Application No.: 10/749,706 4 Docket No.: 219002030902

## AMENDMENTS TO THE CLAIMS

 (Currently amended) A method for treating impaired filtration or excretion of a solute in the kidney, comprising:

administering to a patient <u>suffering from decreased renal solute filtration or excretion</u> an effective amount of a vascular endothelial growth factor (VEGF), wherein filtration or excretion of the solute is improved as compared to the pre-treatment condition of the patient.

- (Currently amended) The method of claim 1, wherein said VEGF is selected from
  the group consisting of native hVEGF<sub>121</sub> (FIG. 6, SEQ ID NO: 1), native hVEGF<sub>145</sub> (FIG. 7, SEQ ID
  NO: 2), native hVEGF<sub>165</sub> (FIG. 8, SEQ ID NO: 3), native hVEGF<sub>189</sub> (FIG. 9, SEQ ID NO: 4), and
  native hVEGF<sub>206</sub> (FIG. 10, SEO ID NO: 5).
- (Original) The method of claim 1, wherein said VEGF lacks the ability to bind heparin.
- (Currently amended) The method of claim 1, wherein said VEGF is a native hVEGF<sub>121</sub> (FIG. 6: SEO ID NO: 1).
- (Original) The method of claim I, wherein said VEGF comprises a heparin-binding domain modified to render it incapable of binding heparin.
- (Original) The method of claim I, wherein said VEGF comprises an amino acid alteration within its heparin-binding domain.
- (Original) The method of claim 1 comprising the administration of two or more VEGFs.
- (Original) The method of claim 1, wherein said VEGF is coadministered with another angiogenic factor.

Application No.: 10/749,706 5 Docket No.: 219002030902

- 9. (Original) The method of claim 1, wherein the solute is sodium chloride.
- (Original) The method of claim 1, wherein the impaired filtration or excretion of solutes comprises an aspect of hypertension.
- (New) The method of claim 5, wherein the modified VEGF is selected from the group consisting of native hVEGF<sub>145</sub> (SEQ ID NO: 2), native hVEGF<sub>165</sub> (SEQ ID NO: 3), native hVEGF<sub>189</sub> (SEQ ID NO: 4), and native hVEGF<sub>206</sub> (SEQ ID NO: 5).
- (New) The method of claim 5, wherein the modified VEGF is selected from the group consisting of native hVEGF<sub>145</sub> (SEQ ID NO: 2), native hVEGF<sub>165</sub> (SEQ ID NO: 3), native hVEGF<sub>189</sub> (SEQ ID NO: 4), and native hVEGF<sub>206</sub> (SEQ ID NO: 5).